Release Date: January 31, 2025
Expiration Date: January 31, 2026
Activity Overview
Although it continues to remain a deadly form of cancer, management of small cell lung cancer has been transformed with the introduction of novel immunotherapy-based approaches, bringing the potential of long-term disease control across multiple lines of therapy. In this program, 2 experts in the management of lung cancer discuss the current treatment landscape, as well as the novel therapies in development for extensive-stage disease.
Target Audience
This educational initiative will be directed toward global medical oncologists and pulmonologists. This activity will reach the needs of the health care team by fostering collaboration between pulmonologists and medical oncologists in formulating a management plan for patients with NSCLC, SCLC, and LCNEC-L who have targetable mutations.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Identify clinical and safety data for bispecific T-cell–engaging antibodies targeting DLL3 in the treatment of SCLC and LCNEC-L.
Jacob Sands, MD
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Amgen, Harpoon Therapeutics; Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Lilly, Medtronic, PharmaMar, Sanofi.
Carl M. Gay, MD, PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AstraZeneca. Consultant: AstraZeneca, Genentech; Advisor: Abdera Therapeutics, AstraZeneca, Catalyst Pharmaceuticals, Daiichi Sankyo, G1 Therapeutics, Jazz Pharmaceuticals, Monte Rosa Therapeutics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.